[go: up one dir, main page]

MA47210B1 - Nouveaux derivés de phenyl - Google Patents

Nouveaux derivés de phenyl

Info

Publication number
MA47210B1
MA47210B1 MA47210A MA47210A MA47210B1 MA 47210 B1 MA47210 B1 MA 47210B1 MA 47210 A MA47210 A MA 47210A MA 47210 A MA47210 A MA 47210A MA 47210 B1 MA47210 B1 MA 47210B1
Authority
MA
Morocco
Prior art keywords
phenyl derivatives
methyl
new phenyl
diabetes
new
Prior art date
Application number
MA47210A
Other languages
English (en)
Other versions
MA47210A (fr
Inventor
Shaharyar M Khan
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Priority claimed from PCT/US2018/012491 external-priority patent/WO2018129258A1/fr
Publication of MA47210A publication Critical patent/MA47210A/fr
Publication of MA47210B1 publication Critical patent/MA47210B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau dérivé de phényle, le 5-[(2,4-dinitrophénoxy)méthyl]-l-méthyl-2-nitro-lh-imidazole ou un sel pharmaceutiquement acceptable de celui-ci, qui est utile pour réguler l'activité des mitochondries, réduire l'adiposité, traiter des maladies comprenant le diabète et des complications associées au diabète.
MA47210A 2017-01-06 2018-01-05 Nouveaux derivés de phenyl MA47210B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762443244P 2017-01-06 2017-01-06
PCT/US2018/012491 WO2018129258A1 (fr) 2017-01-06 2018-01-05 Nouveaux dérivés de phényle

Publications (2)

Publication Number Publication Date
MA47210A MA47210A (fr) 2019-11-13
MA47210B1 true MA47210B1 (fr) 2022-05-31

Family

ID=81940336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47210A MA47210B1 (fr) 2017-01-06 2018-01-05 Nouveaux derivés de phenyl

Country Status (1)

Country Link
MA (1) MA47210B1 (fr)

Also Published As

Publication number Publication date
MA47210A (fr) 2019-11-13

Similar Documents

Publication Publication Date Title
SA519402076B1 (ar) مشتقات فينيل جديدة
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
EP4302826A3 (fr) Agonistes du récepteur du peptide de type glucagon 1
EP3828164A4 (fr) Nouveau composé chimère (autotac) ciblant l'autophagie, et composition pour prévenir, soulager ou traiter des maladies par dégradation de protéine cible le comprenant
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
IT1256282B (it) Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica
PH12021551998A1 (en) Novel heterotricyclic derivative compound and use of same
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
HUS000503I2 (hu) Midosztaurin vagy annak egy sója
MA57699B1 (fr) Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf
ZA202103431B (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MX2021011081A (es) Derivados de nicorandil.
MX388589B (es) Nuevo uso terapeutico de h3-ligandos.
EA202190316A1 (ru) Конденсированное производное лактама
MA47210B1 (fr) Nouveaux derivés de phenyl
MX2022003270A (es) Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.
EP1864976A4 (fr) Dérivé de propane-1,3-dione ou sel de celui-ci
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
MA51836B1 (fr) Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
WO2019059868A3 (fr) Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz
EA201991180A1 (ru) Новые фенильные производные
MX2023012030A (es) Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4).